Citagem
Formulation
Each vial contains:
Gemcitabine (as hydrochloride) 200 mg or 1 g

Gemcitabine

Citagem®

Prescription Drug

Indications

Ovarian cancer
In combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months following platinum-based therapy

Breast cancer
In combination with paclitaxel, for the first-line treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior therapy should have included an anthracycline, unless clinically indicated.

Non-small cell lung cancer (NSCLC)
Alone or in combination with cisplatin, for the first-line treatment of patients with inoperable, locally advanced (inoperable stage IIIA or IIIB) or metastatic (stage IV) NSCLC. Monotherapy may be considered in elderly patients or those with performance status 2.

Pancreatic cancer
For the first-line treatment of adult patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas. It can be used as first-line therapy or second-line therapy in patients with 5-fluorouracil-refractory pancreatic cancer.

Bladder cancer
In combination with cisplatin, for the treatment of advanced transitional cell bladder cancer (muscle invasive stage IV tumors with or without metastases.)

Dosage and Administration

For more information on safety, precaution and other information about this product, please see the Product Insert.

Please consult your physician and other healthcare providers before taking any prescription medicines found on this site. The contents found on this page are for information purposes only. It should not be construed as a substitute for professional medical advise and should not be relied upon in that regard. You undertake to carefully read all product packaging and labels prior to use.

Caution: Food, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.